We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Inspire (INSP) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Inspire Medical Systems (INSP - Free Report) will report quarterly earnings of $0.06 per share in its upcoming release, pointing to a year-over-year increase of 120.7%. It is anticipated that revenues will amount to $197.65 million, exhibiting an increase of 28.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Inspire metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Geographic Revenue- United States' should arrive at $191.01 million. The estimate suggests a change of +29.5% year over year.
The consensus estimate for 'Geographic Revenue- All other countries' stands at $6.68 million. The estimate suggests a change of +15.5% year over year.
According to the collective judgment of analysts, 'New U.S. Medical Centers' should come in at 53. The estimate compares to the year-ago value of 62.
The combined assessment of analysts suggests that 'Total U.S. Medical Centers' will likely reach 1,369. Compared to the current estimate, the company reported 1,107 in the same quarter of the previous year.
Analysts expect 'New U.S. sales territories' to come in at 13. The estimate is in contrast to the year-ago figure of 13.
Analysts predict that the 'Total U.S. sales territories' will reach 323. The estimate is in contrast to the year-ago figure of 274.
Shares of Inspire have experienced a change of -4.9% in the past month compared to the +1.8% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), INSP is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Inspire (INSP) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Inspire Medical Systems (INSP - Free Report) will report quarterly earnings of $0.06 per share in its upcoming release, pointing to a year-over-year increase of 120.7%. It is anticipated that revenues will amount to $197.65 million, exhibiting an increase of 28.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Inspire metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Geographic Revenue- United States' should arrive at $191.01 million. The estimate suggests a change of +29.5% year over year.
The consensus estimate for 'Geographic Revenue- All other countries' stands at $6.68 million. The estimate suggests a change of +15.5% year over year.
According to the collective judgment of analysts, 'New U.S. Medical Centers' should come in at 53. The estimate compares to the year-ago value of 62.
The combined assessment of analysts suggests that 'Total U.S. Medical Centers' will likely reach 1,369. Compared to the current estimate, the company reported 1,107 in the same quarter of the previous year.
Analysts expect 'New U.S. sales territories' to come in at 13. The estimate is in contrast to the year-ago figure of 13.
Analysts predict that the 'Total U.S. sales territories' will reach 323. The estimate is in contrast to the year-ago figure of 274.
View all Key Company Metrics for Inspire here>>>
Shares of Inspire have experienced a change of -4.9% in the past month compared to the +1.8% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), INSP is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>